Tharimmune (NASDAQ:THAR) Shares Up 3.1% – Here’s Why

Shares of Tharimmune, Inc. (NASDAQ:THAR) rose 3.1% during mid-day trading on Friday. The stock traded as high as $2.37 and last traded at $2.31. Approximately 476,139 shares traded hands during trading, a decline of 68% from the average daily volume of 1,476,877 shares. The stock had previously closed at $2.24.

Tharimmune Price Performance

The stock has a 50-day moving average price of $2.11 and a 200 day moving average price of $2.82. The firm has a market cap of $96.97 million, a price-to-earnings ratio of -0.64 and a beta of 1.43.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Tharimmune stock. Clear Street Group Inc. bought a new position in shares of Tharimmune, Inc. (NASDAQ:THAR) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 1,671,836 shares of the company’s stock, valued at approximately $5,066,000. Clear Street Group Inc. owned about 4.43% of Tharimmune at the end of the most recent quarter. Hedge funds and other institutional investors own 1.16% of the company’s stock.

About Tharimmune

Tharimmune, Inc is a clinical-stage biotechnology company focused on developing therapies for immune-mediated and inflammatory diseases. The company’s research and development programs are aimed at conditions with significant unmet medical needs, including disorders associated with chronic itching and inflammation.

Tharimmune’s lead candidate is TH104, a buccal film formulation of aprepitant being developed for the treatment of chronic pruritus associated with cholestatic liver disease.